구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Activated NK Cells (M-CENK, M-CENK (Activated NK Cells)) ImmunityBio, Inc.·High-risk Prostate Cancer 59 trials |
|---|---|
Overview Program | M-CENK (Activated NK Cells) |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | High-risk Prostate Cancer |
Overview Indication | High-risk Prostate Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | viral vectors can further confine scFv activity to tumors, coupling checkpoint blockade with |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarkers and dynamic metabolic monitoring may support patient stratification and response prediction |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity and variable patient responses remain challenges |
Toxicology CRS | Reported |
Clinical Safety signal | hepatotoxicity and variable patient responses remain challenges |
Clinical Reported OS | 94.4 |
Clinical Result source | ClinicalTrials.gov NCT01700946 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01700946 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Activated NK Cells (M-CENK, M-CENK (Activated NK Cells)) ImmunityBio, Inc.·High-risk Prostate Cancer 59 trials |
|---|---|
Overview Program | M-CENK (Activated NK Cells) |
Overview Company | ImmunityBio, Inc. |
Overview Modality | CGT |
Overview Target | High-risk Prostate Cancer |
Overview Indication | High-risk Prostate Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | viral vectors can further confine scFv activity to tumors, coupling checkpoint blockade with |
MoA Mechanism | target of rapamycin (mTOR) pathway |
MoA Biomarker | biomarkers and dynamic metabolic monitoring may support patient stratification and response prediction |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | hepatotoxicity and variable patient responses remain challenges |
Toxicology CRS | Reported |
Clinical Safety signal | hepatotoxicity and variable patient responses remain challenges |
Clinical Reported OS | 94.4 |
Clinical Result source | ClinicalTrials.gov NCT01700946 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT01700946 |
추천 비교
추천 비교